866-997-4948(US-Canada Toll Free)

Dyslipidemia - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Metabolic Disorders

No. of Pages : 203 Pages

Dyslipidemia - Pipeline Review, H1 2014

Summary

Global Markets Directs, Dyslipidemia - Pipeline Review, H1 2014, provides an overview of the Dyslipidemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dyslipidemia Overview 9
Therapeutics Development 10
Pipeline Products for Dyslipidemia - Overview 10
Pipeline Products for Dyslipidemia - Comparative Analysis 11
Dyslipidemia - Therapeutics under Development by Companies 12
Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 17
Dyslipidemia - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Dyslipidemia - Products under Development by Companies 22
Dyslipidemia - Products under Investigation by Universities/Institutes 26
Dyslipidemia - Companies Involved in Therapeutics Development 27
Johnson & Johnson 27
Amgen Inc. 28
Eli Lilly and Company 29
GlaxoSmithKline plc 30
Daiichi Sankyo Company, Limited 31
Merck & Co., Inc. 32
Euroscreen S.A. 33
Takeda Pharmaceutical Company Limited 34
Teijin Pharma Limited 35
Novartis AG 36
Biocon Limited 37
Chong Kun Dang Pharmaceutical Corp. 38
Dr. Reddy's Laboratories Limited 39
Glenmark Pharmaceuticals Ltd. 40
Kissei Pharmaceutical Co., Ltd. 41
Kowa Company, Ltd. 42
Zydus Cadila Healthcare Limited 43
GW Pharmaceuticals plc 44
Genfit SA 45
Ligand Pharmaceuticals, Inc. 46
Nippon Chemiphar Co., Ltd. 47
Jenrin Discovery, Inc. 48
Lipicard Technologies Limited 49
Cadila Pharmaceuticals Ltd. 50
Spherix Incorporated 51
Arisaph Pharmaceuticals, Inc. 52
Alder Biopharmaceuticals Inc. 53
Catabasis Pharmaceuticals, Inc. 54
aRigen Pharmaceuticals, Inc. 55
Cardax Pharmaceuticals, Inc. 56
Cerenis Therapeutics SA 57
Essentialis, Inc. 58
Esperion Therapeutics, Inc. 59
Pharmena SA 60
Reviva Pharmaceuticals Inc. 61
Kotobuki Pharmaceutical Co., Ltd. 62
Kadmon Pharmaceuticals, LLC 63
Acasti Pharma Inc. 64
Kareus Therapeutics, SA 65
High Point Pharmaceuticals, LLC 66
Dezima Pharma B.V. 67
Matinas BioPharma, Inc. 68
Biospherics.net Incorporated 69
Dyslipidemia - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 75
Assessment by Route of Administration 79
Assessment by Molecule Type 81
Drug Profiles 83
anacetrapib - Drug Profile 83
K-877 - Drug Profile 85
Nicotinic Acid - Drug Profile 86
(rosuvastatin calcium + ezetimibe) - Drug Profile 87
Centatin - Drug Profile 88
DEZ-001 - Drug Profile 89
GFT-505 - Drug Profile 90
DRL-17822 - Drug Profile 92
K-877 - Drug Profile 93
ZYH-7 - Drug Profile 94
1-Methylnicotinamide - Drug Profile 95
ETC-1002 - Drug Profile 97
diazoxide CR - Drug Profile 99
evacetrapib - Drug Profile 101
(niacin + aspirin) - Drug Profile 103
GWP-42003 - Drug Profile 104
KD-026 - Drug Profile 106
S-556971 - Drug Profile 107
GWP-42004 - Drug Profile 108
MGL-3196 - Drug Profile 109
ARI-3037-MO - Drug Profile 111
ZYT-1 - Drug Profile 112
HPP-593 - Drug Profile 113
NC-2400 - Drug Profile 114
TAP-311 - Drug Profile 115
S-556971 - Drug Profile 116
DS-1442 - Drug Profile 117
K-312 - Drug Profile 118
SPX-8522876 - Drug Profile 119
ARMAK-105 - Drug Profile 120
JD-2000 Series - Drug Profile 121
JD-5000 Series - Drug Profile 122
JD-6000 Series - Drug Profile 123
CDX-085 - Drug Profile 124
NKPL-66 - Drug Profile 126
Thyroid Receptor-Beta Agonist Program - Drug Profile 128
GRC-9332 - Drug Profile 129
(statin + niacin + aspirin) - Drug Profile 130
NC-2400 - Drug Profile 131
HDL Receptor Enhancer - Drug Profile 132
(SPX-106 + D-tagatose) - Drug Profile 133
ESN-282 - Drug Profile 135
CAT-2000 Series - Drug Profile 136
Cardiovascular Program - Drug Profile 137
ALD-306 - Drug Profile 138
4655-K09 - Drug Profile 139
TEI-M01361 - Drug Profile 140
SPX-100 - Drug Profile 141
KTA-439 - Drug Profile 142
CKD-519 - Drug Profile 143
ND-630 - Drug Profile 144
First Generation Diacylglycerol Acyltransferase Inhibitor - Drug Profile 145
Second Generation Diacylglycerol Acyltransferase Inhibitor - Drug Profile 146
MAT-9001 - Drug Profile 147
ZLN-005 - Drug Profile 148
LT-5421 - Drug Profile 149
LT-5423 - Drug Profile 150
Peroxibrate - Drug Profile 151
BSN-852 - Drug Profile 152
GSK-2041706 - Drug Profile 153
LP-071 - Drug Profile 154
latanoprost - Drug Profile 155
Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia - Drug Profile 156
DGAT-1 - Drug Profile 157
ESN-JJ - Drug Profile 158
RP-7000 - Drug Profile 159
Peptides For Dyslipidemic and Vascular Disorders - Drug Profile 160
Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 161
ALD-317 - Drug Profile 162
Dyslipidemia - Recent Pipeline Updates 163
Dyslipidemia - Dormant Projects 183
Dyslipidemia - Discontinued Products 186
Dyslipidemia - Product Development Milestones 188
Featured News & Press Releases 188
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 198
Disclaimer 198

List of Table

List of Tables
Number of Products under Development for Dyslipidemia, H1 2014 15
Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 18
Number of Products under Development by Companies, H1 2014 (Contd..1) 19
Number of Products under Development by Companies, H1 2014 (Contd..2) 20
Number of Products under Development by Companies, H1 2014 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Comparative Analysis by Late Stage Development, H1 2014 23
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Development, H1 2014 25
Comparative Analysis by Unknown Stage Development, H1 2014 26
Products under Development by Companies, H1 2014 27
Products under Development by Companies, H1 2014 (Contd..1) 28
Products under Development by Companies, H1 2014 (Contd..2) 29
Products under Development by Companies, H1 2014 (Contd..3) 30
Products under Investigation by Universities/Institutes, H1 2014 31
Dyslipidemia - Pipeline by Johnson & Johnson, H1 2014 32
Dyslipidemia - Pipeline by Amgen Inc., H1 2014 33
Dyslipidemia - Pipeline by Eli Lilly and Company, H1 2014 34
Dyslipidemia - Pipeline by GlaxoSmithKline plc, H1 2014 35
Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 36
Dyslipidemia - Pipeline by Merck & Co., Inc., H1 2014 37
Dyslipidemia - Pipeline by Euroscreen S.A., H1 2014 38
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 39
Dyslipidemia - Pipeline by Teijin Pharma Limited, H1 2014 40
Dyslipidemia - Pipeline by Novartis AG, H1 2014 41
Dyslipidemia - Pipeline by Biocon Limited, H1 2014 42
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 43
Dyslipidemia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 44
Dyslipidemia - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 45
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 46
Dyslipidemia - Pipeline by Kowa Company, Ltd., H1 2014 47
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 48
Dyslipidemia - Pipeline by GW Pharmaceuticals plc, H1 2014 49
Dyslipidemia - Pipeline by Genfit SA, H1 2014 50
Dyslipidemia - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 51
Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H1 2014 52
Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H1 2014 53
Dyslipidemia - Pipeline by Lipicard Technologies Limited, H1 2014 54
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2014 55
Dyslipidemia - Pipeline by Spherix Incorporated, H1 2014 56
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014 57
Dyslipidemia - Pipeline by Alder Biopharmaceuticals Inc., H1 2014 58
Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 59
Dyslipidemia - Pipeline by aRigen Pharmaceuticals, Inc., H1 2014 60
Dyslipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2014 61
Dyslipidemia - Pipeline by Cerenis Therapeutics SA, H1 2014 62
Dyslipidemia - Pipeline by Essentialis, Inc., H1 2014 63
Dyslipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2014 64
Dyslipidemia - Pipeline by Pharmena SA, H1 2014 65
Dyslipidemia - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 66
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2014 67
Dyslipidemia - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 68
Dyslipidemia - Pipeline by Acasti Pharma Inc., H1 2014 69
Dyslipidemia - Pipeline by Kareus Therapeutics, SA, H1 2014 70
Dyslipidemia - Pipeline by High Point Pharmaceuticals, LLC, H1 2014 71
Dyslipidemia - Pipeline by Dezima Pharma B.V., H1 2014 72
Dyslipidemia - Pipeline by Matinas BioPharma, Inc., H1 2014 73
Dyslipidemia - Pipeline by Biospherics.net Incorporated, H1 2014 74
Assessment by Monotherapy Products, H1 2014 75
Assessment by Combination Products, H1 2014 76
Number of Products by Stage and Target, H1 2014 79
Number of Products by Stage and Mechanism of Action, H1 2014 82
Number of Products by Stage and Route of Administration, H1 2014 85
Number of Products by Stage and Molecule Type, H1 2014 87
Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2014 168
Dyslipidemia - Dormant Projects, H1 2014 188
Dyslipidemia - Dormant Projects (Contd..1), H1 2014 189
Dyslipidemia - Dormant Projects (Contd..2), H1 2014 190
Dyslipidemia - Discontinued Products, H1 2014 191
Dyslipidemia - Discontinued Products (Contd..1), H1 2014 192

List of Chart

List of Figures
Number of Products under Development for Dyslipidemia, H1 2014 15
Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 17
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Products, H1 2014 25
Assessment by Monotherapy Products, H1 2014 75
Assessment by Combination Products, H1 2014 76
Number of Products by Top 10 Target, H1 2014 77
Number of Products by Stage and Top 10 Target, H1 2014 78
Number of Products by Top 10 Mechanism of Action, H1 2014 80
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 81
Number of Products by Top 10 Route of Administration, H1 2014 84
Number of Products by Stage and Top 10 Route of Administration, H1 2014 85
Number of Products by Top 10 Molecule Type, H1 2014 86
Number of Products by Stage and Top 10 Molecule Type, H1 2014 87

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *